| Document |
Document Title |
|
WO/2018/207192A1 |
Methods of treating leukodystrophy are provided. Accordingly there is provided a method of treating leukodystrophy in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent capable of...
|
|
WO/2018/197324A1 |
The present invention refers to a process for reacting an alkyl aryl ketone obtaining thereby the corresponding aryl oxirane or α-functionalized alkyl aryl ketal, the aryl oxirane or α-functionalized alkyl aryl ketal obtained by the pr...
|
|
WO/2018/197325A1 |
The present invention refers to a process for the preparation of an α-functionalized ketone, an α-functionalized ketone obtained by said process, a photopolymerizable composition comprising the α-functionalized ketone and at least one...
|
|
WO/2018/196860A1 |
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...
|
|
WO/2018/197360A1 |
A process for the manufacture of vortioxetine HBr α-form is provided.
|
|
WO/2018/193297A1 |
The present invention provides compounds which are modulators of RORϒ and their use for the treatment of diseases or conditions mediated by RORϒ. Further, the present invention relates to processes of preparing such compounds, their ta...
|
|
WO/2018/194976A1 |
Methods of reducing neuronal sensitivity, thereby reducing inflammation and chronic pain, are disclosed herein. Particularly disclosed are methods of administrating the apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE1/Ref-1) inh...
|
|
WO/2018/192323A1 |
Disclosed are applications of spermidine and its derivative. Based on existing protein structure data and small molecular data, the inventor performs screening by means of software-based computational analysis to obtain compounds that ca...
|
|
WO/2018/187740A1 |
Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of ag...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/181884A1 |
The objective of the present invention is to provide a novel compound inhibiting the entry of a filovirus into a cell, a medical composition, an anti-filovirus agent, or a filovirus entry inhibitor containing the compound, as well as a m...
|
|
WO/2018/182639A1 |
The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAO...
|
|
WO/2018/178142A1 |
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...
|
|
WO/2018/172696A1 |
The invention relates to ionic liquids comprising the association of a cation of the following formula (I), in which -R1 is an acyclic hydrocarbonated group, n is a whole number between 0 and 3, and m is a whole number between 1 and 4, a...
|
|
WO/2018/165718A1 |
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and ...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/166938A1 |
The invention pertains to a process for preparing hydroxyethylethyleneamines, ethyleneamines, or mixtures thereof, and/or ethylene urea derivatives thereof comprising the step of reacting diethanolamine with an amine-functional compound ...
|
|
WO/2018/169880A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.
|
|
WO/2018/169642A1 |
An adhesive article includes a pressure-sensitive adhesive layer with a release liner releasably adhered thereto. The release liner comprises a thermoplastic polymer and a first release agent represented by the formula: Each R1 represent...
|
|
WO/2018/161476A1 |
The present invention relates to the field of pharmaceutical chemistry. Provided are an amide compound and a preparation method and use thereof. The compound can inhibit cancer cell proliferation, thereby treating a cancer. Particularly,...
|
|
WO/2018/159827A1 |
The present invention provides a novel non-steroid-type compound or a salt thereof, having BR-like activity which is useful for regulating plant growth, an agricultural composition containing the compound or the salt thereof, and uses th...
|
|
WO/2018/154451A1 |
The present invention is related to an improved process for the preparation and purification of crystalline polymorph of Vortioxetine hydrobromide of Formula-I and Vortioxetine hydrochloride of Formula-Ia. The process according to presen...
|
|
WO/2018/151633A1 |
The present invention relates to a method for producing a compound of formula I, where B is, independently, hydrogen or [see appropriate figure], wherein no more than one B is hydrogen; D is NR1 or O; R1 is H, R, C1-C4 alkyl, unsubstitut...
|
|
WO/2018/150344A1 |
The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200μ, D50 35-90μ and D5 7-30μ as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hy...
|
|
WO/2018/150906A1 |
This liquid crystal display device 10 is provided with: a pair of substrates which have conductive films 14, 15, respectively; a liquid crystal layer 12 which is arranged between the pair of substrates and contains liquid crystals; and a...
|
|
WO/2018/149991A1 |
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...
|
|
WO/2018/138359A1 |
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of R...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/138354A1 |
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of R...
|
|
WO/2018/139326A1 |
Provided are: a friction-reducing agent containing neither sulfur nor phosphorus and having excellent friction-reducing properties; and a lubricating oil composition containing the friction-reducing agent. The friction-reducing agent com...
|
|
WO/2018/134695A1 |
The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or sa...
|
|
WO/2018/136792A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2018/130625A1 |
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...
|
|
WO/2018/130942A1 |
The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.
|
|
WO/2018/129609A1 |
Compounds of formula (II) are useful in modulating voltage-gated sodium channel activity. Their preparation and use for reducing the severity of convulsant activity in a subject, for example in the treatment of epilepsy, is presented.
|
|
WO/2018/129552A1 |
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...
|
|
WO/2018/122359A1 |
The present invention relates to a compound of the following formula (I). The invention also relates to uses thereof as a chromophore as such or for building pigments displaying special optical effects, including metal-like reflection.
|
|
WO/2018/122867A1 |
This invention comprises a stable oral dispersible thin film and a process of making the same, the film comprising a 4-Diphenylmethyl-1-piperazinyl derivative or its pharmaceutically acceptable salts; characterized by, during storage of ...
|
|
WO/2018/115421A1 |
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2018/116285A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, X1, X2, m and n are as defined herein, which are active as modulators of retinoid-related orphan re...
|
|
WO/2018/119263A1 |
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...
|
|
WO/2018/115443A1 |
The invention relates to a method for producing an amine oxide by oxidation of a tertiary amine in a reactor under continuous introduction of tertiary amine in a reaction fluid and export of amine oxide, wherein a suitable surface-to-vol...
|
|
WO/2018/110669A1 |
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and meth...
|
|
WO/2018/108698A1 |
The invention relates to a method for producing ethanolamines and/or ethyleneamines in the gas phase by reacting ethylene glycol with ammonia in the presence of an amination catalyst. The method is characterized in that the amination cat...
|
|
WO/2018/107112A1 |
Embodiments are directed to compounds of the formulae (I), (Ia), (Ib), (II), (IIa) (III), (IV), (V), and (VI); methods for treating cancer with one or more compounds of the formulae (I), (Ia), (Ib), (II), (IIa); (III), (IV), (V), and (VI...
|
|
WO/2018/104305A1 |
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...
|
|
WO/2018/099966A1 |
The present invention relates to a process for the conversion of 2-aminoethanol to ethane-1,2- diamine and/or linear polyethylenimines of the formula H2N-[CH2CH2NH] n -CH2CH2NH2 wherein n≥ 1 comprising (i) providing a catalyst comprisi...
|
|
WO/2018/099964A1 |
The present invention relates to a process for the conversion of 2-aminoethanol to ethane-1,2-diamine and/or linear polyethylenimines of the formula H2N-[CH2CH2NH]n-CH2CH2NH2 wherein n ≥1 comprising : (i) providing a catalyst comprisin...
|
|
WO/2018/097126A1 |
Compounds represented by formula (I) or salts thereof. A fungicide or plant disease control agent containing as an active ingredient at least one selected from the group consisting of said compounds and salts thereof. In formula (I), Ar ...
|
|
WO/2018/093949A1 |
Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and comp...
|
